These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

539 related articles for article (PubMed ID: 22519451)

  • 1. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
    Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases, inflammation and atherosclerosis: therapeutic perspectives.
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Clin Chem Lab Med; 2004 Feb; 42(2):121-31. PubMed ID: 15061349
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Matrix metalloproteinases: their biological functions and clinical implications.
    Hijova E
    Bratisl Lek Listy; 2005; 106(3):127-32. PubMed ID: 16026148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix metalloproteinase inhibition after myocardial infarction: a new approach to prevent heart failure?
    Creemers EE; Cleutjens JP; Smits JF; Daemen MJ
    Circ Res; 2001 Aug; 89(3):201-10. PubMed ID: 11485970
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
    Janssens S; Lijnen HR
    Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammatory mechanisms in atherosclerosis: the impact of matrix metalloproteinases.
    Siasos G; Tousoulis D; Kioufis S; Oikonomou E; Siasou Z; Limperi M; Papavassiliou AG; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1132-48. PubMed ID: 22519444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Myocardial remodeling in viral heart disease: possible interactions between inflammatory mediators and MMP-TIMP system.
    Pauschinger M; Chandrasekharan K; Schultheiss HP
    Heart Fail Rev; 2004 Jan; 9(1):21-31. PubMed ID: 14739765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and function of matrix metalloproteinases and TIMPs.
    Nagase H; Visse R; Murphy G
    Cardiovasc Res; 2006 Feb; 69(3):562-73. PubMed ID: 16405877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinases and atherosclerosis.
    Watanabe N; Ikeda U
    Curr Atheroscler Rep; 2004 Mar; 6(2):112-20. PubMed ID: 15023295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Matrix metalloproteinases and atherosclerosis. Therapeutic aspects].
    Beaudeux JL; Giral P; Bruckert E; Foglietti MJ; Chapman MJ
    Ann Biol Clin (Paris); 2003; 61(2):147-58. PubMed ID: 12702469
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Granulocytes in coronary thrombus evolution after myocardial infarction--time-dependent changes in expression of matrix metalloproteinases.
    Li X; de Boer OJ; Ploegmaker H; Teeling P; Daemen MJ; de Winter RJ; van der Wal AC
    Cardiovasc Pathol; 2016; 25(1):40-6. PubMed ID: 26490693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
    Vanhoutte D; Schellings M; Pinto Y; Heymans S
    Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix metalloproteinases and their inhibitors in bone: an overview of regulation and functions.
    Varghese S
    Front Biosci; 2006 Sep; 11():2949-66. PubMed ID: 16720367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multidimensional Contribution of Matrix Metalloproteinases to Atherosclerotic Plaque Vulnerability: Multiple Mechanisms of Inhibition to Promote Stability.
    Ruddy JM; Ikonomidis JS; Jones JA
    J Vasc Res; 2016; 53(1-2):1-16. PubMed ID: 27327039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interplay of matrix metalloproteinases, tissue inhibitors of metalloproteinases and their regulators in cardiac matrix remodeling.
    Li YY; McTiernan CF; Feldman AM
    Cardiovasc Res; 2000 May; 46(2):214-24. PubMed ID: 10773225
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis.
    George SJ
    Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
    Krebber MM; van Dijk CGM; Vernooij RWM; Brandt MM; Emter CA; Rau CD; Fledderus JO; Duncker DJ; Verhaar MC; Cheng C; Joles JA
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TIMPs and cardiac remodeling: 'Embracing the MMP-independent-side of the family'.
    Vanhoutte D; Heymans S
    J Mol Cell Cardiol; 2010 Mar; 48(3):445-53. PubMed ID: 19799912
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matrix metalloproteinases.
    Zitka O; Kukacka J; Krizkova S; Huska D; Adam V; Masarik M; Prusa R; Kizek R
    Curr Med Chem; 2010; 17(31):3751-68. PubMed ID: 20846107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix metalloproteinases in cardiovascular disease.
    Liu P; Sun M; Sader S
    Can J Cardiol; 2006 Feb; 22 Suppl B(Suppl B):25B-30B. PubMed ID: 16498509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.